Close Window
Aetna Aetna
Clinical Policy Bulletin:
Meniere's Disease Surgery
Number: 0514


Policy

Aetna considers any of the following surgical procedures medically necessary for the treatment of chronic refractory Meniere's disease (see selection criteria in the Appendix of the background section):

Surgical procedures non-destructive to hearing:

  • Endolymphatic mastoid shunt
  • Endolymphatic sac decompression
  • Lateral semi-circular canal plugging
  • Perilymphatic fistula patching
  • Sacculotomy
  • Tympanostomy tube insertion
  • Vestibular nerve decompression
  • Vestibular neurectomy (nerve section) or neurotomy (including middle fossa or retrosigmoid vestibular neurotomy).

Surgical procedures destructive to hearing:

  • Cochleosacculotomy
  • Intra-tympanic gentamicin
  • Labyrinthectomy
  • Translabyrinthine vestibular neurectomy
  • Vestibulocochlear neurectomy

Note: For bilateral Meniere's disease, ablative treatments are relatively contraindicated due to the risks of bilateral vestibular and cochlear hypofunction.

Aetna considers either of the following surgical procedures experimental and investigational for the treatment of chronic refractory Meniere's disease because their effectiveness has not been established:

  • Cochleostomy with neurovascular transplant
  • Tenotomy of the stapedius and tensor tympani muscles.


Background

Meniere's disease (MD) is a pathological condition of the inner ear characterized by vertigo, tinnitus and a progressive loss of hearing.  Delayed MD can develop in an ear that was damaged years earlier, usually by viral or bacterial infection.  The majority of patients with MD also experience a sense of fullness and pressure in the area of the affected ear.  This disorder affects male and female equally; it may occur in children, but has a peak onset between 20 and 50 years of age.  The incidence of disease affecting both ears increases to over 40 % with long-term follow-up.  Moreover, it has been reported that a high percentage of patients (57 %) had complete resolution of symptoms in 2 years.

The key pathological finding for patients with MD is an increase in the volume of endolymph, in conjunction with distention of the whole endolymphatic system (known as endolymphatic hydrops).  However, the exact cause of MD is still unclear, and no treatment has prospectively modified the clinical course of the condition and thereby prevented the progressive hearing loss.  Conservative management of patients with MD may include dietary salt restriction (1 to 2 g sodium daily) with or without diuretic (e.g., hydrochlorothiazide, dyazide, furosemide, amiloride, acetazolamide, and methazolamide), avoidance of caffeine, alcohol and nicotine.  For acute attacks, vestibular suppressants (e.g., benzodiazepines and diazepam) or anti-emetics (e.g., anti-cholinergics such as glycopyrrolate, anti-dopaminergics such as droperidol, prochlorperazine, and anti-histamines such as dimenhydrinate, diphenhydramine, meclizine, and promethazine) have been used.  Medical ablation of the inner ear with systemic administration of ototoxic aminoglycosides, such as streptomycin and gentamicin, has been useful in advanced bilateral MD when poor but aidable hearing precludes surgical intervention.  Moreover, the indications for this approach are limited, especially with the advent of intra-tympanic placement of gentamicin.

For MD patients whose vertiginous symptoms are disabling and refractory to dietary and medical treatments, surgery may be the last resort in achieving relief.  In general, surgical procedures for MD can be categorized as non-destructive or destructive regarding to hearing.  The former includes endolymphatic sac surgery and vestibular nerve section (vestibular neurectomy), while the latter includes labyrinthectomy (extirpation of the labyrinth) and cochleosacculotomy.

Endolymphatic sac surgery is the most frequently employed conservative surgical approach for patients with MD when hearing is still serviceable.  It has been reported to achieve complete or substantial control of vertigo in 81 % of patients, with significant improvement in hearing in about 20 % of patients.  Although it has shown to be less likely to completely eliminate vertigo than vestibular nerve section, endolymphatic sac surgery has been reported to be a low morbidity procedure.  Endolymphatic sac decompression and sacculotomy are two common types of endolymphatic sac surgery.  In the former procedure, some of the bone surrounding the inner ear is removed.  In some cases, endolymphatic sac decompression is coupled with the placement of an endolymphatic shunt.  Sacculotomy entails the implantation of a permanent device that allows endolymph to drain out of the inner ear whenever pressure builds up.

Brinson et al (2007) compared the effectiveness of endolymphatic mastoid shunt (EMS, n = 88) versus endolymphatic sac decompression (ESD, n = 108) without sac incision for the treatment of MD.  The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) guidelines for the diagnosis and evaluation of therapy in MD were used to retrospectively identify suitable candidates for the study.  All patients who failed medical management and underwent either EMS or ESD were selected for review using the AAO-HNS guidelines.  The study was carried out at a tertiary care neurotology private practice. EMS and ESD were equally effective in reducing the incidence and severity of vertigo attacks with significant improvement in 67 % and 66 % of patients, respectively.  The authors concluded that both EMS and ESD are effective, non-destructive alternatives for patients who have failed medical management of MD with similar long-term hearing outcomes.

Available medical literature suggests that vestibular nerve section can be performed by exposing the middle fossa or the posterior fossa.  The posterior fossa vestibular neurectomy can be further divided into the retrolabyrinthine approach, the retrosigmoid-internal auditory canal approach, and the combined retrolabyrinthine-retrosigmoid approach.  Vestibular nerve section has been shown to be generally very effective in the control of vertigo.  According to available literature, vestibular nerve section is contraindicated in persons with vertigo arising from the only hearing ear (i.e., the other ear is deaf); central nervous system disease; persons in poor medical condition; persons with ataxia; and in most cases of bilateral MD.

Labyrinthectomy is indicated for patients with symptoms who have poor or non-serviceable hearing.  There are several approaches to the labyrinth -- transcanal labyrinthectomy with section of the posterior ampullary nerve, transmastoid labyrinthectomy, and transmeatal cochloevestibular neurectomy.  For the older patients (greater than 60 years of age), available medical literature suggests that a transmastoid labyrinthectomy may be preferable to a transcanal labyrinthectomy because the incidence of permanent post-surgical imbalance is less with the former approach.  Labyrinthectomy has been reported to produce similar or better results than vestibular neurectomy.  Cochleosacculotomy creates a permanent fistula in the cochlear duct by passing a small pick through the round window.  It is mainly used for elderly patients with poor hearing who are unable to tolerate a prolonged operation.

Lacombe (2009) stated that spontaneous recovery or central compensation makes surgical procedures rare in patients with vertigo.  The main target in treating MD is to promote vestibular compensation, which is possible only with a non-progressive and stable deficit leading to readjustment of vestibular reflexes.  Surgical procedures can be classified as non-destructive (endolymphatic sac decompression, vestibular nerve decompression, patching of perilymphatic fistulas), selectively destructive (middle fossa or retrosigmoid vestibular neurotomy, lateral semi-circular canal plugging) and destructive (labyrinthectomy).  Surgical indications essentially concern incapacitating vertigo and depend mainly on hearing status.  In MD, vestibular neurotomy can be regarded as the gold standard considering its good results on vertiginous episodes; however, scoring with functional and quality-of-life scales bring out residual deficiency in some cases.

In a prospective, follow-up study, Charpiot and colleagues (2010) assessed the safety and effectiveness lateral semi-circular canal plugging to control vertigo in severe MD.  A total of 28 MD patients with refractory vertigo and severe disability (functional scale 5 or 6) were included in this study.  Lateral semi-circular canal plugging was performed in the pathological ear for each patient.  The evaluation of therapy followed the guidelines for diagnosis and evaluation of therapy in MD.  Hearing, frequency of vertigo, and functional disability were assessed in the early follow-up (6 months) for all the patients and in the late follow-up (2 years) for 16 patients.  In addition, canal paresis was evaluated by the caloric test.  No vital complication occurred.  The hearing was preserved in 82 % of cases.  Lateral semi-circular canal plugging induced in all cases canal paresis that was persistent after 2 years.  After 2 years (n = 16), the control of vertigo was complete or substantial in 75 % of cases (restoration of a normal life = 62.5 %; no functional restriction =12.5 %).  The authors concluded that lateral semi-circular canal plugging is a safe procedure that induces canal paresis and allows a good control of vertigo.  In view of these results, lateral semi-circular canal plugging should be a therapeutic option for controlling rotatory vertigo in severe MD.

In a review on bilateral MD, Nabi and Parnes (2009) stated that for bilateral MD, ablative treatments are relatively contraindicated due to the risks of bilateral vestibular and cochlear hypofunction.

In a Cochrane review, Pullens et al (2011) evaluated the effectiveness of intra-tympanic gentamicin in the treatment of vertigo in MD.  These investigators searched the Cochrane Ear, Nose and Throat Disorders Group Trials Register; the Cochrane Central Register of Controlled Trials (CENTRAL); PubMed; EMBASE; CINAHL; Web of Science; BIOSIS Previews; Cambridge Scientific Abstracts; ISRCTN and additional sources for published and unpublished trials.  The date of the most recent search was June 30, 2010.  All randomized or quasi-randomized controlled trials of intra-tympanic gentamicin versus placebo, or versus another treatment for MD were selected for analysis.  Two review authors independently assessed trial quality and extracted data.  They contacted study authors for further information.  These investigators identified 2 trials, involving 50 participants, which fulfilled the inclusion criteria.  Both of these trials are prospective, double-blind, placebo-controlled randomized clinical trials on the effect of intra-tympanic gentamicin on vertigo complaints.  Both of these trials found a significant reduction in vertigo complaints in the gentamicin group when compared to the placebo group.  Due to clinical heterogeneity these researchers could not perform a meta-analysis.  The authors concluded that based on the results of the 2 included studies, intra-tympanic gentamicin seems to be an effective treatment for vertigo complaints in MD, but carries a risk of hearing loss.

Gawecki et al (2012) estimated the results of treatment of MD with intra-tympanic injections of gentamicin.  A total of 37 patients with defined, pharmacological treatment resistant MD were injected intra-tympanic with 0.3 ml (12 mg) of gentamicin once or few times with 7 days or longer breaks and a number of injections depended on the reaction of the inner ear.  These investigators estimated the patients' subjective feelings and results of equilibrium and hearing organ examination in early (3 months) and late (2 years) period after treatment.  Complete control of vertigo (class A) was achieved in 84.6 %, and complete and essential control (class A and B) in 96.1 %.  Hearing deterioration usually mild or moderate was observed directly after treatment in 16.2 % and after 2 years in 23 % patients.  The results of pure tone audiometry showed deterioration of hearing in 16.2 % (early) and 26.9 % (late).  In 1 patient hearing deterioration was essential.  The authors concluded that intra-tympanic injections of gentamicin are effective and not troublesome method of treatment of pharmacological treatment resistant MD.  In most of patients hearing can be preserved, but they should be always informed about possible risk of hearing deterioration. The number of injections and breaks between them depends on the effect of therapy and of expectations of patients.

An UpToDate review on “Meniere disease” (Dinces and Rauch, 2013) states that “Destructive procedures for the treatment of Meniere disease include intratympanic gentamicin injection, surgical labyrinthectomy, and vestibular nerve section.  In general, destructive techniques are better suited to patients who have failed medical therapy and who have unilateral disease”.

The National Coverage Determination (NCD) for “Cochleostomy with Neurovascular Transplant for Meniere's Disease” stated that “While there are 2 recognized surgical procedures used in treating MD (decompression of the endolymphatic hydrops and labyrinthectomy), there is no scientific evidence supporting the safety and effectiveness of cochleostomy with neurovascular transplant in treatment of Meniere's syndrome.  Accordingly, Medicare does not cover cochleostomy with neurovascular transplant for treatment of MD”.

In an interventional cohort study, Loader et al (2012) compared the unique long-term results of tenotomy of the stapedius and tensor tympani muscles in definite MD refractory to medical treatment and presented a hypothesis on why tenotomy seems effective.  The study sample comprised 30 patients (15 males, 15 females; average age of 57 +/- 13.1 years) with definite MD (AAO-HNS criteria, 1995).  Patients were evaluated pre- and post-operatively using pure tone audiometry, AAO-HNS questionnaires regarding vertigo attacks, functional level scores, and tinnitus, and were followed-up for 2 to 9 years.  Post-operative values were calculated for the patient collective as a whole and consequently divided into 3 equal post-operative terms of 3 years each.  A statistically significant improvement of inner ear hearing levels post-operatively (p = 0.041) and a major reduction in vertigo attacks in all groups (p < 0.001) with complete absence of attacks in 26/30 patients was noted.  Results remained constant up to 9 years post-operatively.  Although tinnitus persisted, the intensity was lower overall (p = 0.013).  Based on the immediate and persistent reduction of vertigo and a clear improvement in hearing function and functional scales, the authors concluded that tenotomy is effective in unilateral, definite MD.  They stated that the findings of this study laid the foundation for future prospective, randomized controlled trials.

Furthermore, UpToDate reviews on “Meniere disease” (Dinces and Rauch, 2013) and “Treatment of vertigo” (Furman and Barton, 2013) do not mention the use of cochleostomy and tenotomty as therapeutic options.

Appendix

Selection criteria for surgery for Meniere's disease:

  1. Member has disabling vertigo; and
  2. Member has exhibited symptoms (hearing loss, tinnitus, vertigo) for at least 2 years; and
  3. Member has failed conservative management, including dietary restrictions (avoidance of caffeine, alcohol and nicotine; low sodium), and medical therapy (anti-emetic, diuretic, and vestibular suppressants); and
  4. Member has unilateral Meniere's disease and hearing loss is severe to profound in the involved ear (for labyrinthectomy only).
 
CPT Codes / HCPCS Codes / ICD-9 Codes
CPT codes covered if selection criteria are met:
64716
69433
69436
69676
69801
69805
69806
69905
69910
69915
69950
CPT codes not covered for indications listed in the CPB:
Tenotomy of the stapedius and tensor tympani muscles:
No specific code
ICD-9 codes covered if selection criteria are met:
386.00 Meniere's disease, unspecified
386.01 Active Meniere's disease, cochleovestibular
386.02 Active Meniere's disease, cochlear
386.03 Active Meniere's disease, vestibular
ICD-9 codes not covered for indications listed in the CPB:
386.04 Inactive Meniere's disease
Other ICD-9 codes related to the CPB:
320 - 349.9 Diseases of the central nervous system
388.30 - 388.32 Tinnutis
389.00 - 389.9 Hearing loss
780.4 Dizziness and giddiness
781.2 Abnormality of gait
781.3 Lack of coordination


The above policy is based on the following references:
  1. Goksu N, Bayazit Y, Beder L. Posterior fossa vestibular nerve section for the management of peripheral vertigo. Eur Arch Otorhinolaryngol. 1999;256(5):230-232.
  2. Rosenberg SI. Vestibular surgery for Meniere's disease in the elderly: A review of techniques and indications. Ear Nose Throat J. 1999;78(6):443-446.
  3. Tewary AK, Riley N, Kerr AG. Long-term results of vestibular nerve section. J Laryngol Otol. 1998;112(12):1150-1153.
  4. Sajjadi H, Paparella MM, Williams T. Endolymphatic sac enhancement surgery in elderly patients with Meniere's disease. Ear Nose Throat J. 1998;77(12):975-982.
  5. Langman AW, Lindeman RC. Surgical labyrinthectomy in the older patient. Otolaryngol Head Neck Surg. 1998;118(6):739-742.
  6. Saeed SR. Diagnosis and treatment of Meniere's disease. Br Med J. 1998;316:368-372.
  7. Grant IL, Welling DB. The treatment of hearing loss in Meniere's disease. Otolaryngol Clin North Am. 1997;30(6):1123-1144.
  8. Silverstein H, Rosenberg S, Arruda J, Isaacson JE. Surgical ablation of the vestibular system in the treatment of Meniere's disease. Otolaryngol Clin North Am. 1997;30(6):1075-1095.
  9. Brookes GB. The role of vestibular nerve section in Meniere's disease. Ear Nose Throat J. 1997;76(9):652-663.
  10. Knox GW, McPherson A. Meniere's disease: Differential diagnosis and treatment. Am Fam Physician. 1997;55(4):1185-1194.
  11. Atlas JT, Parnes LS. Intratympanic gentamicin titration therapy for intractable Meniere's disease. Am J Otol. 1999;20(3):357-363.
  12. Silverstein H, Arruda J, Rosenberg SI, et al. Direct round window membrane application of gentamicin in the treatment of Meniere's disease. Otolaryngol Head Neck Surg. 1999;120(5):649-655.
  13. Moffat DA. Endolymphatic sac surgery: Analysis of 100 operations. Clin Otolaryngol. 1994;19:261-266.
  14. Schwager K, Baier G, El-Din N, et al. Revision surgery after saccotomy for Meniere's disease: Does it make sense? Eur Arch Otorhinolaryngol. 2002;259(5):239-242.
  15. Fukuhara T, Silverman DA, Hughes GB, et al. Vestibular nerve sectioning for intractable vertigo: Efficacy of simplified retrosigmoid approach. Otol Neurotol. 2002;23(1):67-72.
  16. Moody-Antonio S, House JW. Hearing outcome after concurrent endolymphatic shunt and vestibular nerve section. Otol Neurotol. 2003;24(3):453-459.
  17. Kitahara T, Kondoh K, Morihana T, et al. Surgical management of special cases of intractable Meniere's disease: Unilateral cases with intact canals and bilateral cases. Ann Otol Rhinol Laryngol. 2004;113(5):399-403.
  18. Kaylie DM, Jackson CG, Gardner EK. Surgical management of Meniere's disease in the era of gentamicin. Otolaryngol Head Neck Surg. 2005;132(3):443-450.
  19. Van de Heyning PH, Wuyts F, Boudewyns A. Surgical treatment of Meniere's disease. Curr Opin Neurol. 2005;18(1):23-28.
  20. Durland WF Jr, Pyle GM, Connor NP. Endolymphatic sac decompression as a treatment for Meniere's disease. Laryngoscope. 2005;115(8):1454-1457.
  21. Paparella MM. Endolymphatic sac revision for recurrent intractable Meniere's disease. Otolaryngol Clin North Am. 2006;39(4):713-721, vi.
  22. Brinson GM, Chen DA, Arriaga MA. Endolymphatic mastoid shunt versus endolymphatic sac decompression for Meniere's disease. Otolaryngol Head Neck Surg. 2007;136(3):415-421.
  23. Kitahara T, Kubo T, Okumura S, Kitahara M. Effects of endolymphatic sac drainage with steroids for intractable Meniere's disease: A long-term follow-up and randomized controlled study. Laryngoscope. 2008;118(5):854-861.
  24. Li CS, Lai JT. Evaluation of retrosigmoid vestibular neurectomy for intractable vertigo in Ménière's disease: An interdisciplinary review. Acta Neurochir (Wien). 2008;150(7):655-661.
  25. Nabi S, Parnes LS. Bilateral Ménière's disease. Curr Opin Otolaryngol Head Neck Surg. 2009;17(5):356-362.
  26. Lacombe H. Surgery for vertigo. Neurochirurgie. 2009;55(2):268-271.
  27. Charpiot A, Rohmer D, Gentine A. Lateral semicircular canal plugging in severe Ménière's disease: A clinical prospective study about 28 patients. Otol Neurotol. 2010;31(2):237-240.
  28. Pullens B, Giard JL, Verschuur HP, van Benthem PP. Surgery for Ménière's disease. Cochrane Database Syst Rev. 2010;(1):CD005395.
  29. Albera R, Canale A, Parandero F, et al. Surgical indication in Menière's disease therapy: Clinical and epidemiological aspects. Eur Arch Otorhinolaryngol. 2011;268(7):967-972.
  30. Goto F, Tsutsumi T, Ogawa K. Lateral semicircular canal plugging with endolymphatic sac decompression as new surgical treatment for intractable Meniere's disease. Acta Otolaryngol. 2012;132(8):893-895.
  31. Pullens B, van Benthem PP. Intratympanic gentamicin for Meniere's disease or syndrome. Cochrane Database Syst Rev. 2011;(3):CD008234.
  32. Gawecki W, Szyfter W, LÄ…czkowska-Przybylska J, Szyfter-Harris J. The long-term results of treatment of Ménière's disease with intratympanic injections of gentamicin. Otolaryngol Pol. 2012;66(1):20-26.
  33. Schlegel M, Vibert D, Ott SR, et al. Functional results and quality of life after retrosigmoid vestibular neurectomy in patients with Meniere's disease. Otol Neurotol. 2012;33(8):1380-1385.
  34. NCD for cochleostomy with neurovascular transplant for Meniere's disease. Available at: http://cms.hhs.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=67&ncdver=1&bc=AgAAQAAAAAAA&. Accessed May 6, 2013.
  35. Loader B, Beicht D, Hamzavi JS, Franz P. Tenotomy of the middle ear muscles causes a dramatic reduction in vertigo attacks and improves audiological function in definite Meniere's disease. Acta Otolaryngol. 2012;132(5):491-497.
  36. Dinces EA, Rauch SD. Meniere disease. Last reviewed April, 2013. UpToDate Inc. Waltham, MA.
  37. Furman JM, Barton JJS. Treatment of vertigo. Last reviewed April, 2013. UpToDate Inc. Waltham, MA.


email this page   


Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.
Aetna
Back to top